Preclinical Evaluation Of Max-40279, A Flt3/Fgfr Dual Kinase Inhibitor For Treatment Of Acute Myeloid Leukemia

Background: In newly diagnosed AML patients, the prevalence is about 30% for FLT3-ITD. FLT3-ITD is associated with disease progression, increased risk of relapse and shorter overall survival. Targeting FLT3 receptor tyrosine kinase has shown encouraging results in treating FLT3-mutated AML. Responses, however, are not sustained and acquired resistance has been a clinical challenge. Treatment options to overcome resistance are currently the focus of research.